Baricitinib plus remdesivir reduced recovery time in a phase 3 clinical trial of 1033 patients. The treatment is implied for patients who require extra oxygen, mechanical ventilation, or ECMO. Medscape Medical News
Read More
- Tue. Nov 26th, 2024
Latest News